DRG Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of schizophrenia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's schizophrenia forecast will answer the following questions:

  • How will improvements in survival change the number of people living with a diagnosis of schizophrenia?
  • Of all people diagnosed with schizophrenia, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of schizophrenia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following schizophrenia subpopulations:

  • Diagnosed prevalent cases by cognitive effect status.
  • Diagnosed prevalent cases by depression comorbidity status.
  • Diagnosed prevalent cases by drug-treatment status.
  • Diagnosed prevalent cases by symptom status.

Note: Coverage may vary by country.

Table of contents

  • Schizophrenia - Epidemiology - Mature Markets
    • Introduction
      • Updates 2018
      • Key Findings
      • Diagnosed Prevalence of Schizophrenia per 1,000 Among Adults in 2017 and 2037
      • Patient Flow Diagram for Schizophrenia Across All Countries Under Study in 2017
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Schizophrenia over the Next Twenty Years
      • Analysis of Diagnosed Prevalent Cases by Cognitive Impairment Status
    • Epidemiology Data
    • Epidemiology Populations
      • Diagnosed Prevalent Cases
      • Diagnosed Incident Cases
      • Cognitive Impairment Cases
      • Comorbidity Cases
      • Drug-Treated Prevalent Cases
      • Symptom Status Cases
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Schizophrenia
        • Studies Excluded from the Analysis of Schizophrenia
      • Risk/Protective Factors
        • Risk/Protective Factors for Schizophrenia
      • Bibliography

Author(s): Nishant Kumar, MPH; Swarali Tadwalkar

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space.

Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.


Related Reports

Schizophrenia - Landscape & Forecast - Disease Landscape And Forecast G7

The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are al...

View Details

Schizophrenia| Disease Landscape and Forecast | G7 | 2020

The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also ava...

View Details

Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

View Details

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details